A new formulation of Ocrevus (ocrelizumab), given as a 10-minute under-the-skin injection, was comparable to the approved intravenous version…
Articles by Marisa Wexler, MS
Inflammation in the membranes around the brain may trigger an inflammatory response that can spread into nearby brain tissue, a…
The biopharmaceutical company Imcyse has signed on to a new project that aims to use artificial intelligence (AI) to…
Treatment with estriol, a hormone that’s produced during pregnancy, reduced disease severity and promoted myelin repair in the cortex —…
The PoNS device — officially the Portable Neuromodulation Stimulator, designed to help improve walking ability in people with…
Ocrevus (ocrelizumab) appears to be more effective than rituximab at reducing relapse activity in people with relapsing-remitting…
It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field…
The protein DDX39B is a master regulator of immune tolerance, or the immune system’s ability to distinguish self from potentially…
For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but…
Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of…
People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after…
Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability…
Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with…
Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new…
The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis…
The average rate of relapses for multiple sclerosis (MS) in the modern era is lower than it has been…
Treatment with the cannabis oral spray nabiximols helped to relieve spasticity — increased muscle stiffness and spasms common in…
Stem cell therapy is better than Gilenya (fingolimod) or Tysabri (natalizumab) at reducing relapse rates and easing disability…
An updated snapshot of multiple sclerosis (MS) in the U.S. — provided by new population estimates from a study…
When the immune system launches an attack to fight off infection with the Epstein-Barr virus, immune cells can accidentally…
People with multiple sclerosis (MS) who have never received treatment with a disease-modifying therapy tend to have better…
A newly developed laboratory model using tadpoles can help determine the remyelinating potential of new multiple sclerosis (MS) therapies…
Blood levels of the nerve damage marker NfL seem to spike to very high levels around times of disease activity…
Rehabilitation therapy that utilizes virtual reality can help to improve balance and reduce the fear of falling for people with…
Nearly half of the people with relapsing forms of multiple sclerosis (MS) treated early with Ocrevus (ocrelizumab) in…
More than 80% of patients with relapsing forms of multiple sclerosis (MS) given Kesimpta (ofatumumab) continuously for up…
There was no evidence of multiple sclerosis (MS) disease activity for at least two years in patients who underwent…
More than 90% of Black and Hispanic patients with multiple sclerosis (MS) treated with Ocrevus (ocrelizumab) in a…
Treatment with Aubagio (teriflunomide) significantly reduces the risk that adults with radiologically isolated syndrome (RIS) will develop symptoms of…
Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of multiple sclerosis (MS), according…